Top 20 global biopharma firms see 1.7 per cent market cap growth to $3.7 billion in 2024 amid policy challenges Read more
Novo Nordisk’s Ozempic gains USFDA approves to cut risk of diabetic kidney disease progression Read more
Race for approval of first oral GLP-1R drug in obesity intensifies with four in phase III trials: GlobalData Read more
Hims & Hers Health to introduce generic Liraglutide in 2025 amid growing demand for weight-loss medications Read more